Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

Bench-to-bedside development of agonists and antagonists of luteinizing hormone–releasing hormone for treatment of advanced prostate cancer

(2015) Ferenc G. Rick et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors

(2015) Joanna L Gillis et al.   Oncotarget

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

π–π Interaction Energies as Determinants of the Photodimerization of Mono-, Di-, and Triazastilbenes

(2014) Alexander A. Parent et al.   JOURNAL OF ORGANIC CHEMISTRY

Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone

(2014) Mary Nakazawa et al.   Hormones & Cancer

A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo

(2013) H. Kuruma et al.   MOLECULAR CANCER THERAPEUTICS

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer

(2013) Ferenc Rick et al.   OncoTargets and Therapy

An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)

(2013) M. Korpal et al.   Cancer Discovery

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

(2013) J. D. Joseph et al.   Cancer Discovery

Overcoming mutation-based resistance to antiandrogens with rational drug design

(2013) Minna D Balbas et al.   eLife

Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists

(2012) Satoshi Yamamoto et al.   BIOORGANIC & MEDICINAL CHEMISTRY

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

(2012) N. J. Clegg et al.   CANCER RESEARCH

Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

(2012) Himisha Beltran et al.   EUROPEAN UROLOGY

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

(2012) Y Li et al.   ONCOGENE

Alternatively spliced androgen receptor variants

(2011) Scott M Dehm et al.   ENDOCRINE-RELATED CANCER

Cyclobutane Derivatives As Novel Nonpeptidic Small Molecule Agonists of Glucagon-Like Peptide-1 Receptor

(2011) Qing Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Development of a Benzopyran-Containing Androgen Receptor Antagonist to Treat Antiandrogen-Resistant Prostate Cancer

(2010) Sangmi Oh et al.   ChemMedChem

FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells

(2010) L. Ni et al.   MOLECULAR AND CELLULAR BIOLOGY

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cyclobutane-containing peptides: Evaluation as novel metallocarboxypeptidase inhibitors and modelling of their mode of action

(2009) Daniel Fernández et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Differential Presentation of Protein Interaction Surfaces on the Androgen Receptor Defines the Pharmacological Actions of Bound Ligands

(2009) John David Norris et al.   CHEMISTRY & BIOLOGY

The Homeodomain Protein HOXB13 Regulates the Cellular Response to Androgens

(2009) John D. Norris et al.   MOLECULAR CELL

Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists

(2009) J. D. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor

(2008) Ken-ichi Wakabayashi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer

(2008) J. A. Locke et al.   CANCER RESEARCH

Targeting the androgen receptor pathway in prostate cancer

(2008) Yu Chen et al.   CURRENT OPINION IN PHARMACOLOGY

Blocking Estrogen Signaling After the Hormone: Pyrimidine-Core Inhibitors of Estrogen Receptor-Coactivator Binding

(2008) Alexander A. Parent et al.   JOURNAL OF MEDICINAL CHEMISTRY

Orthidines A–E, tubastrine, 3,4-dimethoxyphenethyl-β-guanidine, and 1,14-sperminedihomovanillamide: potential anti-inflammatory alkaloids isolated from the New Zealand ascidian Aplidium orthium that act as inhibitors of neutrophil respiratory burst

(2008) A. Norrie Pearce et al.   TETRAHEDRON